Immunodominant CD4(+) responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant

There is increasing evidence showing the involvement of CD4(+) T cells in initiating and maintaining antitumor immune responses. NY-ESO-1 is expressed by various tumors but not normal tissues except testis. We conducted a cancer clinical trial by using full-length NY-ESO-1 protein formulated with IS...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Chen, Qiyuan, Jackson, Heather, Parente, Phillip, Luke, Tina, Rizkalla, Mark, Tai, Tsin Yee, Zhu, He-Cheng, Mifsud, Nicole A., Dimopoulos, Nektaria, Masterman, Kelly-Anne, Hopkins, Wendie, Goldie, Heather, Maraskovsky, Eugene, Green, Simon, Miloradovic, Lena, McCluskey, James, Old, Lloyd J., Davis, Ian D., Cebon, Jonathan, Chen, Weisan
Médium: Artigo
Jazyk:Inglês
Vydáno: National Academy of Sciences 2004
Témata:
Biological Sciences
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC438982/
https://ncbi.nlm.nih.gov/pubmed/15197261
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.0403271101
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky